Media stories about CONMED (NASDAQ:CNMD) have trended somewhat positive on Friday, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CONMED earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned press coverage about the medical technology company an impact score of 46.2645464263737 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern Sentiment’s analysis:
Several analysts recently issued reports on CNMD shares. BidaskClub downgraded CONMED from a “sell” rating to a “strong sell” rating in a report on Wednesday, December 27th. Zacks Investment Research upgraded CONMED from a “hold” rating to a “buy” rating and set a $57.00 target price on the stock in a research report on Wednesday, January 3rd. Needham & Company LLC raised their target price on CONMED from $58.00 to $71.00 and gave the company a “buy” rating in a research report on Thursday, February 1st. Finally, ValuEngine upgraded CONMED from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $58.50.
CNMD opened at $63.00 on Friday. CONMED has a 12 month low of $43.88 and a 12 month high of $64.99. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.44 and a current ratio of 2.38. The company has a market capitalization of $1,770.57, a P/E ratio of 33.33, a price-to-earnings-growth ratio of 2.56 and a beta of 0.59.
CONMED (NASDAQ:CNMD) last posted its earnings results on Wednesday, January 31st. The medical technology company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.65 by $0.04. CONMED had a return on equity of 8.96% and a net margin of 6.97%. The firm had revenue of $222.60 million for the quarter, compared to analysts’ expectations of $212.17 million. During the same period last year, the firm earned $0.54 EPS. The firm’s revenue was up 9.1% compared to the same quarter last year. research analysts expect that CONMED will post 2.14 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, April 5th. Investors of record on Thursday, March 15th were given a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 1.27%. The ex-dividend date of this dividend was Wednesday, March 14th. CONMED’s dividend payout ratio is currently 42.33%.
In other news, CFO Luke A. Pomilio sold 19,620 shares of CONMED stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $60.19, for a total transaction of $1,180,927.80. Following the transaction, the chief financial officer now directly owns 600 shares in the company, valued at approximately $36,114. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Terence M. Berge sold 3,868 shares of CONMED stock in a transaction on Friday, March 9th. The shares were sold at an average price of $62.45, for a total value of $241,556.60. Following the transaction, the vice president now owns 19,908 shares in the company, valued at $1,243,254.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 46,473 shares of company stock worth $2,874,693. 2.62% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/20/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-conmed-cnmd-stock-price.html.
CONMED Company Profile
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products.
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.